Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 425, Issue 1, Pages 43-50Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/S0014-2999(01)01159-1
Keywords
fluvoxamine; flesinoxan; anxiety; conditioned fear stress; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor; selective; 5-HT1A receptor agonist
Categories
Ask authors/readers for more resources
The present study investigated the acute effects of flesinoxan (a selective 5-HT1A receptor agonist), fluvoxamine (a selective serotonin reuptake inhibitor) and their co-administration on the expression of conditioned freezing, and index of anxiety in rats. This study also examined the acute effects of fluvoxamine and flesinoxan following chronic flesinoxan or chronic fluvoxamine on the expression of conditioned freezing. Acute administration of flesinoxan (s.c.; 0.1-3 mg/kg) reduced freezing dose dependently, and fluvoxamine (i.p.) at a high dose (60 mg/kg) reduced freezing significantly. Acute co-administration of fluvoxamine (30 mg/kg) and flesinoxan (0.3 mg/kg) showed an additive inhibitory effect on freezing. Chronic flesinoxan treatment (0.3 mg/kg, for 13 days) did not affect the inhibitory effect of acute flesinoxan treatment, but enhanced that of acute fluvoxamine (30 mg/kg) on conditioned freezing. Chronic fluvoxamine treatment (30 mg/kg, for 13 days) enhanced the inhibitory effect of acute fluvoxamine (30 mg/kg) and the inhibitory effect of acute flesinoxan (0.3 mg/kg) on conditioned freezing. These results suggest that co-administration of a selective serotonin reuptake inhibitor and a 5-HT1A receptor agonist is useful for the treatment of anxiety disorders. (C) 2001 Elsevier Science B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available